PV QA 4 - Poster Viewing Q&A 4
Purpose/Objective(s): To report preliminary safety results of initial 50 cases with early-stage hormone receptor (HR)-positive breast cancer treated with hypofractionated partial breast irradiation using simplified intensity-modulated radiation therapy (sIMRT) technique after breast conservation surgery.
Materials/Methods: From Dec of 2014 to Oct of 2016, fifty women patients aged more than 50 years affected by early-stage hormone receptor (HR)-positive breast cancer, with a maximum pathological size of 25 mm and negative axillary nodes, were enrolled to receive a total dose of 40Gy to the tumor bed in 15 fractions using sIMRT technique at our institute. The primary endpoint was occurrence of ipsilateral breast tumor recurrence (IBTR); the secondary endpoint was radiation-associated toxicity graded according to the common terminology of criteria for adverse events version 4.0 (CTCAE v4.0) issued by the National Cancer Institute; and the main analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov (registration No. NCT03411174).
Results: The median age was 64 (range: 57-74) years old. The median size of the primary tumor was 15 (range: 2-25) mm. At a median follow-up of 23 (range: 13-37) months, no IBTRs were found to develop. The most frequently observed acute adverse event was skin erythema. Grade 1 radiation dermatitis was found to occur in 9 cases (18.0%). No grade 2 or higher radiation dermatitis was observed. 7 patients (14.0%) experienced grade 1 breast pain. Only 1 patient was noted to develop grade 1 breast induration. None were observed to have skin telangiectasis or fatty necrosis.
Conclusion: This preliminary analysis demonstrated that hypofractionated partial breast irradiation delivered with IMRT technique was clinically safe in patients with early-stage HR-positive breast cancer after breast-conserving surgery. Further study with greater number of patients and longer follow-up is warranted.
The asset you are trying to access is locked. Please enter your access key to unlock.